First Mercantile Trust Co. Purchases 250 Shares of Cepheid (CPHD)
First Mercantile Trust Co. boosted its stake in Cepheid (NASDAQ:CPHD) by 6.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,020 shares of the company’s stock after buying an additional 250 shares during the period. First Mercantile Trust Co.’s holdings in Cepheid were worth $124,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its stake in shares of Cepheid by 9.0% in the second quarter. BNP Paribas Arbitrage SA now owns 19,667 shares of the company’s stock valued at $605,000 after buying an additional 1,626 shares during the last quarter. BlackRock Group LTD raised its stake in shares of Cepheid by 19.8% in the first quarter. BlackRock Group LTD now owns 67,730 shares of the company’s stock valued at $2,260,000 after buying an additional 11,213 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of Cepheid by 2.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,829,588 shares of the company’s stock valued at $61,035,000 after buying an additional 36,476 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its stake in shares of Cepheid by 3.1% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 440,520 shares of the company’s stock valued at $13,546,000 after buying an additional 13,119 shares during the last quarter. Finally, Rothschild Asset Management Inc. purchased a new stake in shares of Cepheid during the second quarter valued at $294,000. 95.32% of the stock is currently owned by institutional investors.
Shares of Cepheid (NASDAQ:CPHD) opened at 52.65 on Friday. Cepheid has a 1-year low of $25.09 and a 1-year high of $53.91. The stock has a 50 day moving average price of $46.55 and a 200 day moving average price of $35.35. The firm’s market capitalization is $3.84 billion.
Cepheid (NASDAQ:CPHD) last released its earnings results on Thursday, July 28th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.19. Cepheid had a negative return on equity of 10.20% and a negative net margin of 8.78%. The firm earned $146 million during the quarter, compared to analysts’ expectations of $145.82 million. During the same period in the prior year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Equities research analysts anticipate that Cepheid will post $0.33 earnings per share for the current fiscal year.
Several analysts have recently weighed in on CPHD shares. Cowen and Company lowered Cepheid from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 7th. Barclays PLC raised their target price on Cepheid from $36.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 7th. Zacks Investment Research upgraded Cepheid from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research report on Tuesday, June 28th. Robert W. Baird downgraded Cepheid from an “outperform” rating to a “neutral” rating and set a $53.00 target price for the company. in a research report on Monday, September 12th. Finally, Citigroup Inc. downgraded Cepheid from a “buy” rating to a “neutral” rating and raised their target price for the stock from $44.00 to $53.00 in a research report on Thursday, September 8th. Seventeen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $41.83.
In other news, VP Scott A. Campbell sold 746 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $36.71, for a total value of $27,385.66. Following the completion of the transaction, the vice president now directly owns 10,721 shares in the company, valued at approximately $393,567.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.16% of the stock is owned by insiders.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.